Department of Ear, Nose and Throat, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, High Heaton, Newcastle upon Tyne, NE7 7DN, UK
Department of Ear, Nose and Throat, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, High Heaton, Newcastle upon Tyne, NE7 7DN, UK.
BMJ. 2023 Oct 18;383:e075445. doi: 10.1136/bmj-2023-075445.
To assess the clinical effectiveness of septoplasty.
Multicentre, randomised controlled trial.
17 otolaryngology clinics in the UK's National Health Service.
378 adults (≥18 years, 67% men) newly referred with symptoms of nasal obstruction associated with septal deviation and at least moderate symptoms of nasal obstruction (score >30 on the Nasal Obstruction and Symptom Evaluation (NOSE) scale).
Participants were randomised 1:1 to receive either septoplasty (n=188) or defined medical management (n=190, nasal steroid and saline spray for six months), stratified by baseline symptom severity and sex.
The primary outcome measure was patient reported score on the Sino-Nasal Outcome Test-22 (SNOT-22) at six months, with 9 points defined as the minimal clinically important difference. Secondary outcomes included quality of life and objective nasal airflow measures.
Mean SNOT-22 scores at six months were 19.9 (95% confidence interval 17.0 to 22.7) in the septoplasty arm (n=152, intention-to-treat population) and 39.5 (36.1 to 42.9) in the medical management arm (n=155); an estimated 20.0 points lower (better) for participants randomised to receive septoplasty (95% confidence interval 16.4 to 23.6, P<0.001, adjusted for baseline continuous SNOT-22 score and the stratification variables sex and baseline NOSE severity categories). Greater improvement in SNOT-22 scores was predicted by higher baseline symptom severity scores. Quality of life outcomes and nasal airflow measures (including peak nasal inspiratory flow and absolute inhalational nasal partitioning ratio) improved more in participants in the septoplasty group. Readmission to hospital with bleeding after septoplasty occurred in seven participants (4% of 174 who had septoplasty), and a further 20 participants (12%) required antibiotics for infections.
Septoplasty is a more effective intervention than a defined medical management regimen with a nasal steroid and saline spray in adults with nasal obstruction associated with a deviated nasal septum.
ISRCTN Registry ISRCTN16168569.
评估鼻中隔成形术的临床效果。
多中心、随机对照试验。
英国国民保健署的 17 个耳鼻喉科诊所。
378 名成年人(≥18 岁,67%为男性),新出现与鼻中隔偏曲相关的鼻塞症状,并至少有中度鼻塞症状(NOSE 量表评分>30)。
参与者按基线症状严重程度和性别 1:1 随机分为鼻中隔成形术组(n=188)或规定的药物治疗组(n=190,鼻内类固醇和盐水喷雾治疗 6 个月)。
主要结局测量指标为 6 个月时患者报告的 Sino-Nasal Outcome Test-22(SNOT-22)评分,9 分定义为最小临床重要差异。次要结局包括生活质量和客观鼻腔气流测量。
鼻中隔成形术组(意向治疗人群,n=152)6 个月时 SNOT-22 评分的平均值为 19.9(95%置信区间 17.0 至 22.7),药物治疗组为 39.5(36.1 至 42.9);接受鼻中隔成形术的参与者评分预计低 20.0 分(更好)(95%置信区间 16.4 至 23.6,P<0.001,调整了基线连续 SNOT-22 评分和分层变量性别以及基线 NOSE 严重程度类别)。SNOT-22 评分的改善与较高的基线症状严重程度评分相关。鼻中隔成形术组的生活质量结局和鼻腔气流测量(包括最大鼻吸气流量和绝对吸入性鼻腔分区比)改善更明显。鼻中隔成形术后 7 名参与者(174 名接受鼻中隔成形术的参与者中有 4%)因出血再次住院,另有 20 名参与者(12%)因感染需要抗生素。
鼻中隔成形术是一种比鼻内类固醇和盐水喷雾更有效的治疗方法,在与鼻中隔偏曲相关的鼻塞的成年患者中。
ISRCTN 注册处 ISRCTN85504553。